2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMORecruiting
To evaluate recurrent dysphagia, due to tissue overgrowth or migration, of the SX-Ella stent Esophageal HV in patients with dysphagia from inoperable carcinoma of the distal esophagus or cardia.